Allogene Therapeutics Inc.’s interim Phase I data for its allogeneic chimeric antigen receptor T-cell (CAR-T) therapies, ALLO-501 and ALLO-501A, look increasingly comparable to marketed autologous CAR-Ts in terms of response rates among patients with B-cell non-Hodgkin’s lymphomas, particularly with their added advantage of enabling consolidation treatment. But while those responses look durable so far, a lingering question is whether that durability will continue long enough to approach or match the durable responses seen with their autologous cousins.
South San Francisco, CA-based Allogene announced 19 May data from the ALPHA study of ALLO-501 and the ALPHA2 study of...